These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38115074)
1. Statistical recommendations for count, binary, and ordinal data in rare disease cross-over trials. Geroldinger M; Verbeeck J; Hooker AC; Thiel KE; Molenberghs G; Nyberg J; Bauer J; Laimer M; Wally V; Bathke AC; Zimmermann G Orphanet J Rare Dis; 2023 Dec; 18(1):391. PubMed ID: 38115074 [TBL] [Abstract][Full Text] [Related]
2. A neutral comparison of statistical methods for analyzing longitudinally measured ordinal outcomes in rare diseases. Geroldinger M; Verbeeck J; Thiel KE; Molenberghs G; Bathke AC; Laimer M; Zimmermann G Biom J; 2024 Jan; 66(1):e2200236. PubMed ID: 36890631 [TBL] [Abstract][Full Text] [Related]
3. How to analyze continuous and discrete repeated measures in small-sample cross-over trials? Verbeeck J; Geroldinger M; Thiel K; Hooker AC; Ueckert S; Karlsson M; Bathke AC; Bauer JW; Molenberghs G; Zimmermann G Biometrics; 2023 Dec; 79(4):3998-4011. PubMed ID: 37587671 [TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
5. Composite endpoints, including patient reported outcomes, in rare diseases. Verbeeck J; Dirani M; Bauer JW; Hilgers RD; Molenberghs G; Nabbout R Orphanet J Rare Dis; 2023 Sep; 18(1):262. PubMed ID: 37658423 [TBL] [Abstract][Full Text] [Related]
6. Beyond repeated-measures analysis of variance: advanced statistical methods for the analysis of longitudinal data in anesthesia research. Ma Y; Mazumdar M; Memtsoudis SG Reg Anesth Pain Med; 2012; 37(1):99-105. PubMed ID: 22189576 [TBL] [Abstract][Full Text] [Related]
7. Power and sample size for GEE analysis of incomplete paired outcomes in 2 × 2 crossover trials. Tang Y Pharm Stat; 2021 Jul; 20(4):820-839. PubMed ID: 33738918 [TBL] [Abstract][Full Text] [Related]
8. swdpwr: A SAS macro and an R package for power calculations in stepped wedge cluster randomized trials. Chen J; Zhou X; Li F; Spiegelman D Comput Methods Programs Biomed; 2022 Jan; 213():106522. PubMed ID: 34818620 [TBL] [Abstract][Full Text] [Related]
9. A readily available improvement over method of moments for intra-cluster correlation estimation in the context of cluster randomized trials and fitting a GEE-type marginal model for binary outcomes. Westgate PM Clin Trials; 2019 Feb; 16(1):41-51. PubMed ID: 30295512 [TBL] [Abstract][Full Text] [Related]
10. GEEMAEE: A SAS macro for the analysis of correlated outcomes based on GEE and finite-sample adjustments with application to cluster randomized trials. Zhang Y; Preisser JS; Li F; Turner EL; Toles M; Rathouz PJ Comput Methods Programs Biomed; 2023 Mar; 230():107362. PubMed ID: 36709555 [TBL] [Abstract][Full Text] [Related]
11. Analyzing longitudinal binary data in clinical studies. Li Y; Feng D; Sui Y; Li H; Song Y; Zhan T; Cicconetti G; Jin M; Wang H; Chan I; Wang X Contemp Clin Trials; 2022 Apr; 115():106717. PubMed ID: 35240309 [TBL] [Abstract][Full Text] [Related]
12. Sample-size calculations for studies with correlated ordinal outcomes. Kim HY; Williamson JM; Lyles CM Stat Med; 2005 Oct; 24(19):2977-87. PubMed ID: 16149125 [TBL] [Abstract][Full Text] [Related]
13. Estimating relative risks in multicenter studies with a small number of centers - which methods to use? A simulation study. Pedroza C; Truong VTT Trials; 2017 Nov; 18(1):512. PubMed ID: 29096682 [TBL] [Abstract][Full Text] [Related]
14. Cluster randomised crossover trials with binary data and unbalanced cluster sizes: application to studies of near-universal interventions in intensive care. Forbes AB; Akram M; Pilcher D; Cooper J; Bellomo R Clin Trials; 2015 Feb; 12(1):34-44. PubMed ID: 25475880 [TBL] [Abstract][Full Text] [Related]
15. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102 [TBL] [Abstract][Full Text] [Related]
16. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. Jackson CL; Colborn K; Gao D; Rao S; Slater HC; Parikh S; Foy BD; Kittelson J Clin Trials; 2021 Oct; 18(5):582-593. PubMed ID: 34218684 [TBL] [Abstract][Full Text] [Related]
18. Power and sample size requirements for GEE analyses of cluster randomized crossover trials. Li F; Forbes AB; Turner EL; Preisser JS Stat Med; 2019 Feb; 38(4):636-649. PubMed ID: 30298551 [TBL] [Abstract][Full Text] [Related]
19. The special case of the 2 × 2 table: asymptotic unconditional McNemar test can be used to estimate sample size even for analysis based on GEE. Borkhoff CM; Johnston PR; Stephens D; Atenafu E J Clin Epidemiol; 2015 Jul; 68(7):733-9. PubMed ID: 25510372 [TBL] [Abstract][Full Text] [Related]
20. Improving the analysis of composite endpoints in rare disease trials. McMenamin M; Berglind A; Wason JMS Orphanet J Rare Dis; 2018 May; 13(1):81. PubMed ID: 29788976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]